News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
《大行》摩通升藥明康德(02359.HK)目標價至150元 續予「增持」評級
摩根大通發表研究報告指，藥明康德(02359.HK)管理層對今年收入指引介乎513億至530億元人民幣，當中已計入外匯因素，管理層透露，以固定匯率計算的潛在增長率或約達22%至26%。持續經營業務的在手訂單按年增長28.8%至580億元人民幣，以固定匯率計則增長約34%。摩通提到，藥明康德為滿足強勁需求，管理層指引今年資本開支介乎65億至75億元人民幣，按年...
Reset
Send
The window will close in 5 seconds
《大行》摩通升藥明康德(02359.HK)目標價至150元 續予「增持」評級
Close
Recommend
3
Positive
4
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

摩根大通發表研究報告指，藥明康德(02359.HK)  +1.000 (+0.807%)    Short selling $183.46M; Ratio 100.552%   管理層對今年收入指引介乎513億至530億元人民幣，當中已計入外匯因素，管理層透露，以固定匯率計算的潛在增長率或約達22%至26%。持續經營業務的在手訂單按年增長28.8%至580億元人民幣，以固定匯率計則增長約34%。

摩通提到，藥明康德為滿足強勁需求，管理層指引今年資本開支介乎65億至75億元人民幣，按年增加10億至20億元人民幣。

該行表示，基於藥明康德的指引，上調公司2026至28財年的銷售預測4%至5%，調升其毛利率預測3個百分點，又上調其盈測10%至11%，將目標價由142元升至150元，續予「增持」評級及列作行業首選股。(sl/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.